AstraZeneca (Heart Drug) is Buildings and Property in United Kingdom that focus on Commercialization rights business. They cover business area such as commercialization right, a portfolio, two heart-relate drug, Plendil (felodipine, hypertension, Imdur, an oral extend-release formulation, isosorbide mononitrate, ISMN, angina pectoris, coronary artery disease, marketing, China, divestment.
-
Commercialization Rights
-
2 Kingdom Street
London W2 6BD
England, United Kingdom
Private
commercialization righta portfoliotwo heart-relate drugPlendil (felodipinehypertensionImduran oral extend-release formulationisosorbide mononitrateISMNangina pectoriscoronary artery diseasemarketingChinadivestment
* We use standard office opening hours in near AstraZeneca (Heart Drug)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AstraZeneca (Heart Drug) is Buildings and Property business from United Kingdom that founded in - ( years old in ), AstraZeneca (Heart Drug) business is focusing on Commercialization Rights.
AstraZeneca (Heart Drug) headquarter office and corporate office address is located in 2 Kingdom Street London W2 6BD England, United Kingdom.
AstraZeneca (Heart Drug) was founded in United Kingdom.
In , AstraZeneca (Heart Drug) is currently focus on Commercialization rights sector.
Above is snippet of Google Trends for "Commercialization rights" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AstraZeneca (Heart Drug), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
